Other Species / Isoforms
  CK1E (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S17-p
RLGRKIGsGSFGDIY
0 1
CK1E (human) RLGRKIGsGSFGDIY S17-p
CK1E (mouse) RLGRKIGSGSFGDIY S17
CK1E (rat) RLGRKIGSGSFGDIY S17
T44-p
IKLECVKtKHPQLHI
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, induced
CK1E (human) IKLECVKtKHPQLHI T44-p
CK1E (mouse) IKLECVKTKHPQLHI T44
CK1E (rat) IKLECVKTKHPQLHI T44
K54-ub
PQLHIESkFYkMMQG
0 1
CK1E (human) PQLHIESkFYkMMQG K54-ub
CK1E (mouse) PQLHIESKFYKMMQG K54
CK1E (rat) PQLHIESKFYKMMQG K54
K57-ub
HIESkFYkMMQGGVG
0 1
CK1E (human) HIESkFYkMMQGGVG K57-ub
CK1E (mouse) HIESKFYKMMQGGVG K57
CK1E (rat) HIESKFYKMMQGGVG K57
K140-ub
NFLMGLGkKGNLVYI
0 3
CK1E (human) NFLMGLGkKGNLVYI K140-ub
CK1E (mouse) NFLMGLGkKGNLVYI K140-ub
CK1E (rat) NFLMGLGKKGNLVYI K140
K242-ac
TPIEVLCkGYPSEFS
0 1
CK1E (human) TPIEVLCkGYPSEFS K242-ac
CK1E (mouse) TPIEVLCKGYPSEFS K242
CK1E (rat) TPIEVLCKGYPSEFS K242
K263-ub
RSLRFDDkPDySYLR
0 3
CK1E (human) RSLRFDDkPDySYLR K263-ub
CK1E (mouse) RSLRFDDkPDYSYLR K263-ub
CK1E (rat) RSLRFDDKPDYSYLR K263
Y266-p
RFDDkPDySYLRQLF
0 1
CK1E (human) RFDDkPDySYLRQLF Y266-p
CK1E (mouse) RFDDkPDYSYLRQLF Y266
CK1E (rat) RFDDKPDYSYLRQLF Y266
R321-m1
EERMGQLrGsAtRAL
0 1
CK1E (human) EERMGQLrGsAtRAL R321-m1
CK1E (mouse) EERMGQLRGSAtRAL R321
CK1E (rat) EERMGQLRGSATRAL R321
S323-p
RMGQLrGsAtRALPP
Upstream
Downstream
2 5
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
  • MG132_withdrawal
  • nocodazole
  • thymidine
CK1E (human) RMGQLrGsAtRALPP S323-p
CK1E (mouse) RMGQLRGSAtRALPP S323
CK1E (rat) RMGQLRGSATRALPP S323
T325-p
GQLrGsAtRALPPGP
Upstream
Downstream
2 2
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
CK1E (human) GQLrGsAtRALPPGP T325-p
CK1E (mouse) GQLRGSAtRALPPGP T325-p
CK1E (rat) GQLRGSATRALPPGP T325
T334-p
ALPPGPPtGAtANRL
Upstream
Downstream
2 0
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
CK1E (human) ALPPGPPtGAtANRL T334-p
CK1E (mouse) ALPPGPPTGATANRL T334
CK1E (rat) ALPPGPPTGATANRL T334
T337-p
PGPPtGAtANRLrsA
Upstream
Downstream
2 0
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
CK1E (human) PGPPtGAtANRLrsA T337-p
CK1E (mouse) PGPPTGATANRLRsA T337
CK1E (rat) PGPPTGATANRLRSA T337
R342-m1
GAtANRLrsAAEPVA
0 1
CK1E (human) GAtANRLrsAAEPVA R342-m1
CK1E (mouse) GATANRLRsAAEPVA R342
CK1E (rat) GATANRLRSAAEPVA R342
S343-p
AtANRLrsAAEPVAs
0 7
CK1E (human) AtANRLrsAAEPVAs S343-p
CK1E (mouse) ATANRLRsAAEPVAS S343-p
CK1E (rat) ATANRLRSAAEPVAS S343
S350-p
sAAEPVAstPAsRIQ
0 2
CK1E (human) sAAEPVAstPAsRIQ S350-p
CK1E (mouse) sAAEPVASTPASRIQ S350
CK1E (rat) SAAEPVASTPASRIQ S350
T351-p
AAEPVAstPAsRIQP
0 10
CK1E (human) AAEPVAstPAsRIQP T351-p
CK1E (mouse) AAEPVASTPASRIQQ T351
CK1E (rat) AAEPVASTPASRIQQ T351
S354-p
PVAstPAsRIQPAGN
0 5
CK1E (human) PVAstPAsRIQPAGN S354-p
CK1E (mouse) PVASTPASRIQQTGN S354
CK1E (rat) PVASTPASRIQQAGN S354
T362-p
RIQPAGNtsPRAIsR
Upstream
0 5
Treatment
  • nocodazole
  • thymidine
CK1E (human) RIQPAGNtsPRAIsR T362-p
CK1E (mouse) RIQQTGNTsPRAISR T362
CK1E (rat) RIQQAGNTsPRAISR T362
S363-p
IQPAGNtsPRAIsRV
Upstream
0 41
Treatment
  • nocodazole
  • thymidine
CK1E (human) IQPAGNtsPRAIsRV S363-p
CK1E (mouse) IQQTGNTsPRAISRA S363-p
CK1E (rat) IQQAGNTsPRAISRA S363-p
S368-p
NtsPRAIsRVDRERK
Upstream
Downstream
2 0
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
CK1E (human) NtsPRAIsRVDRERK S368-p
CK1E (mouse) NTsPRAISRADRERK S368
CK1E (rat) NTsPRAISRADRERK S368
S377-p
VDRERKVsMRLHrGA
0 6
CK1E (human) VDRERKVsMRLHrGA S377-p
CK1E (mouse) ADRERKVSMRLHrGA S377
CK1E (rat) ADRERKVSMRLHRGA S377
R382-m1
KVsMRLHrGAPANVs
0 20
CK1E (human) KVsMRLHrGAPANVs R382-m1
CK1E (mouse) KVSMRLHrGAPANVs R382-m1
CK1E (rat) KVSMRLHRGAPANVS R382
S389-p
rGAPANVsssDLtGR
Upstream
Downstream
1 30
Effects on Modified Protein
  • protein degradation
Effects on Biological Processes:
  • transcription, altered
Kinase, in vitro:
  • AMPKA1 (human)
Putative in vivo kinases:
  • AMPKA1 (mouse)
Treatment
  • EGF
  • ischemia
  • nocodazole
  • thymidine
CK1E (human) rGAPANVsssDLtGR S389-p
CK1E (mouse) rGAPANVsSSDLTGR S389-p
CK1E (rat) RGAPANVSSSDLTGR S389
S390-p
GAPANVsssDLtGRQ
Upstream
0 2
Treatment
  • MG132_withdrawal
CK1E (human) GAPANVsssDLtGRQ S390-p
CK1E (mouse) GAPANVsSSDLTGRQ S390
CK1E (rat) GAPANVSSSDLTGRQ S390
S391-p
APANVsssDLtGRQE
0 6
CK1E (human) APANVsssDLtGRQE S391-p
CK1E (mouse) APANVsSSDLTGRQE S391
CK1E (rat) APANVSSSDLTGRQE S391
T394-p
NVsssDLtGRQEVsR
0 6
CK1E (human) NVsssDLtGRQEVsR T394-p
CK1E (mouse) NVsSSDLTGRQEVSR T394
CK1E (rat) NVSSSDLTGRQEVSR T394
S400-p
LtGRQEVsRIPAsQt
0 1
CK1E (human) LtGRQEVsRIPAsQt S400-p
CK1E (mouse) LTGRQEVSRLAAsQt S400
CK1E (rat) LTGRQEVSRIAASQT S400
S405-p
EVsRIPAsQtsVPFD
Upstream
Downstream
2 21
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
  • ischemia
CK1E (human) EVsRIPAsQtsVPFD S405-p
CK1E (mouse) EVSRLAAsQtsVPFD S405-p
CK1E (rat) EVSRIAASQTSVPFD S405
T407-p
sRIPAsQtsVPFDHL
Upstream
Downstream
2 6
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
  • ischemia
CK1E (human) sRIPAsQtsVPFDHL T407-p
CK1E (mouse) SRLAAsQtsVPFDHL T407-p
CK1E (rat) SRIAASQTSVPFDHL T407
S408-p
RIPAsQtsVPFDHLG
Upstream
Downstream
2 23
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • CK1E (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • ciclosporin
  • DHPG
CK1E (human) RIPAsQtsVPFDHLG S408-p
CK1E (mouse) RLAAsQtsVPFDHLG S408-p
CK1E (rat) RIAASQTSVPFDHLG S408